Oxytocin - 5MG

Oxytocin

Oxytocin is a nonapeptide hormone synthesized in the hypothalamus with roles in reproduction, social bonding, and modulation of stress/emotional responses. Beyond parturition and lactation, oxytocin influences anxiety, social cognition, and stress resilience via central actions.^[1–8]

Neuroendocrine & Behavioral Effects

• Oxytocin receptors are expressed across limbic and cortical regions (amygdala, hippocampus, mPFC). Oxytocin release shapes behavioral and neuroendocrine stress responses, suppresses anxiety, and promotes adaptive coping and prosocial behavior.^{[1,2,4,6,8–10]}

Psychiatric & Therapeutic Applications

• Altered oxytocin signaling is linked to anxiety, depression, PTSD, ASD, and schizophrenia. Intranasal oxytocin can modulate socio-emotional networks and shows anxiolytic/anti-stress effects in select populations.^{[1–6,9–12]}

Mechanisms of Action

• Acts via OXTR (GPCR), engaging MAPK/PKC/PLC/CaMK cascades and transcription factors (e.g., CREB, MEF-2), supporting neuronal plasticity and behavioral outcomes; also exhibits anti-inflammatory/antioxidative effects.^[3,7,8,12]

Clinical Evidence & Dosing

• Trials report benefits for stress-related conditions (e.g., anxiety/PTSD): reduced fear, improved social function, modulation of neuroinflammation, and support of allostasis/resilience.^[1,4,6,9,12]
• Typical research dosing: 24–40 IU intranasally. A 10 mg dose (~10,000 IU) is not established in the literature and exceeds common research/clinical protocols.^[1,4,6,7,9]

Safety & Limitations

• Generally well tolerated (e.g., transient nasal irritation, headache). Chronic/high dosing may cause receptor downregulation or paradoxical anxiety. Outcomes may vary by sex, age, adversity history, and OXTR variation.^[9,11]

Summary

Oxytocin (10 mg) is a neuropeptide with pleiotropic effects on stress regulation, social behavior, and emotional well-being. Evidence supports anxiolytic, anti-stress, and pro-social properties, but optimal high-dose regimens and long-term safety remain to be defined.^[1–12]

References

1. Takayanagi Y, Onaka T. Int J Mol Sci. 2021;23(1):150.
2. Grinevich V, Neumann ID. Mol Psychiatry. 2021;26(1):265–279.
3. Marazziti D, et al. Curr Med Chem. 2022;29(35):5615–5687.
4. Zhang S, et al. Cell & Bioscience. 2023;13(1):216.
5. Jin Y, et al. Int J Mol Sci. 2023;24(13):10430.
6. Matsushita H, et al. Neuroscience. 2019;417:1–10.
7. Uvnäs Moberg K, et al. Med Hypotheses. 2019;133:109394.
8. Jurek B, Neumann ID. Physiol Rev. 2018;98(3):1805–1908.
9. Neumann ID, Slattery DA. Biol Psychiatry. 2016;79(3):213–221.
10. Ishak WW, et al. J Affect Disord. 2011;130(1–2):1–9.
11. Yoon S, Kim YK. Prog Neuropsychopharmacol Biol Psychiatry. 2022;116:110531.
12. Wang SC, et al. Int J Mol Sci. 2018;19(12):E3848.

All information provided is for research purposes only.

All COA’s avail upon request by email info@truformlabs.com.

All information provided is for research purposes only.

Storage & Handling (Research Use)

• Lyophilized (dry): Store sealed at −20 °C to −80 °C (long-term), desiccated and light-protected. Short-term (≤2–3 weeks) at 2–8 °C is acceptable.
• After reconstitution: Store at 2–8 °C and use within 7 days, or aliquot immediately and freeze at −20 °C to −80 °C for up to 3 months.
• Avoid degradation: Prepare small aliquots to limit freeze–thaw cycles; keep solutions on ice during handling; minimize exposure to air/light.
• Solvent & pH: Reconstitute as specified for the lot (e.g., sterile saline/bacteriostatic water) at ~pH 7.0–7.4; avoid reactive metals/oxidizers.
• Labeling: Record concentration, solvent, and prep date; follow lab SOPs and any lot-specific stability notes.

All information provided is for research purposes only.